多替阿巴拉米片获批适应症

On January 20, 2019, the State Food and Drug Administration (CFDA) approved Suimeikai (chemical name:), a new compound preparation for AIDS treatment, to enter China. As an innovative single-tablet compound preparation with obvious clinical therapeutic advantages, Dolutegra Abalamid Tablets can provide great convenience for the treatment of AIDS patients and has received priority review and approval from the State Food and Drug Administration. Dolutegravir tablets are an innovative drug for the treatment of HIV/AIDS by ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK). It is currently the only three-in-one compound drug containing dolutegravir (DTG). It has the characteristics of good tolerance, high resistance barrier and few drug interactions. One tablet per day can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and significantly improving their quality of life. 

Thirty years ago, AIDS was almost equivalent to a terminal illness. Through the joint efforts of doctors and scientists, significant progress has been made in AIDS treatment. Currently, AIDS is becoming a controllable chronic disease. As of June 30, 2016, there were more than 620,000 living HIV/AIDS patients reported across the country, more than 190,000 reported deaths, and more than 420,000 patients currently receiving antiretroviral treatment. Dr. Wim Swyzen, MD, head of medical affairs and vice president of GSK China/Hong Kong, said, "Through effective HIV drug treatment, the life spans of HIV patients and healthy people are getting closer and closer. Drug compliance and convenience of medication play an increasingly important role in further improving the quality of life of patients. Currently, there is no drug that can be taken once a day or one tablet at a time on the Chinese market. The approval of doptabalamid tablets fills this gap and meets the urgent need for convenient medication use by doctors and patients." Wim Swyzen, MD, head of medical affairs and vice president of GSK China/Hong Kong. Swyzen said that the CFDA has recently taken positive actions in the review and approval of new drugs. GSK will continue to strengthen its research and development activities in China and strive to introduce more new AIDS drugs, such as two-in-one compound preparations, long-acting preparations, etc. 

It is reported that dolutea palamid tablets have been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients. Following the launch of the new AIDS drug Tevicay last year, this is another new drug from GSK approved for the treatment of AIDS in China. GSK has been bringing AIDS drugs to Chinese patients since 1999. Shuangtaizhi is GSK's first approved AIDS antiviral treatment drug in China.